T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
暂无分享，去创建一个
G. D. Miralles | C. Cohen | M. Greenberg | R. A. Myers | D. Henry | J. Lalezari | N. Bellos | T. Melby | R. Demasi | Ying Zhang | C. Raskino | R. Spence | G. Richmond | Kunthavi Sathasivam | Hugh Murchison | Nicholaos C. Bellos | Robert A. Myers, Jr.